Arginine Metabolism in Pediatric Type 2 Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05477134|
Recruitment Status : Recruiting
First Posted : July 28, 2022
Last Update Posted : February 8, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes||Other: Stable isotope infusion, oral glucose ingestion, intravenous arginine bolus||Not Applicable|
In parallel with the childhood obesity epidemic, type 2 diabetes (T2D) in children is becoming a significant public health concern. The incidence of pediatric T2D increased by 50% during the past decade, and recent data show that T2D accounts for one in four newly-diagnosed diabetes cases in children. Children with T2D have an aggressive disease course and a rapid decline in β-cell function, and many also have multiple cardiovascular disease risk factors at an early age. The disease is characterized by insulin resistance and impaired insulin secretion, but the molecular underpinnings of T2D are not yet fully elucidated. This study aims to uncover the role of arginine metabolism in the pathogenesis of pediatric T2D and the effect of exogenous arginine administration on β-cell function in children with T2D.
Arginine is a known stimulant of insulin secretion in pancreatic β-cells. Nitric oxide (NO) is synthesized from arginine by NO synthase, and arginine stimulates insulin secretion in both NO-mediated and NO-independent mechanisms by stimulating guanylate cyclase, membrane depolarization, and metabolic by-products. The effects of arginine in pancreatic β-cells are dependent on the cells' available arginine concentration. Kinetic techniques using isotope tracer infusions and targeted metabolomics provide a unique opportunity to determine "intracellular" arginine availability and its relative contribution of various pathways to this pool. Such studies in adults with T2D have shown that arginine and NO play roles in the pathogenesis of T2D by affecting insulin secretion and insulin sensitivity. In the preliminary data on children with T2D, the investigators found that children with T2D had lower fasting arginine, citrulline (arginine precursor), and glutamine (citrulline precursor) levels. In this proposal, the investigators will seek kinetic validation of these hypothesis-generating observations to investigate the role of arginine metabolism in pediatric T2D. Our central hypothesis is that children with T2D have inadequate arginine availability (Aim 1), leading to suboptimal β-cell function, which can be restored by exogenous arginine administration (Aim 2). If our hypotheses are proven, arginine supplementation will play a clinically vital role in improving diabetes outcomes in this population as a safe, low-cost, and readily available nutrient.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Arginine Metabolism in Pediatric Type 2 Diabetes|
|Actual Study Start Date :||February 6, 2023|
|Estimated Primary Completion Date :||June 2027|
|Estimated Study Completion Date :||August 2027|
Experimental: The study cohort consisting of children with type 2 diabetes and healthy controls
In Study Day 1, participants will be given a primed dose of stable isotopes followed by continuous intravenous infusions for 5 hours. The investigators will use the following isotopes: U-13C6-Arg, 5,5-2H2-Cit, 15N2-Orn, 2H5-Phe, Na13CO3, and 13C5-Orn.
On Study Day 2, participants will drink a 75-gram glucose solution prior to an oral glucose tolerance test.
On Study Day 3, participants will drink a 75-gram glucose solution and will be injected 5-gram arginine into their veins.
Other: Stable isotope infusion, oral glucose ingestion, intravenous arginine bolus
On separate study days, each participant will have a stable isotope infusion, ingest oral glucose, and be given an intravenous arginine bolus.
- The difference in arginine availability [ Time Frame: 1 day ]Arginine availability will be assessed and compared between children with type 2 diabetes and healthy controls.
- The difference in insulin secretion and the effect of intravenous arginine bolus on insulin secretion [ Time Frame: 1 day ]Insulin secretion will be assessed and compared between children with type 2 diabetes and healthy controls using oral glucose tolerance tests and modified oral glucose tolerance tests including intravenous arginine administration. The effect of arginine bolus on insulin secretion will be compared between the groups.
- The difference in insulin sensitivity and the effect of intravenous arginine bolus on insulin sensitivity [ Time Frame: 1 day ]Insulin sensitivity will be assessed and compared between children with type 2 diabetes and healthy controls using oral glucose tolerance tests and modified oral glucose tolerance tests including intravenous arginine administration. The effect of arginine bolus on insulin sensitivity will be compared between the groups.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||12 Years to 17 Years (Child)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- Children with type 2 diabetes and healthy controls who meet other inclusion criteria outlined below.
- Age and pubertal stage criteria (12- to 17-year-old girls who are postmenarchal, and 14- to 17-year-old boys who are at Tanner stage 5 pubic hair),
- Additional criteria for children with diabetes: i. diagnosis of T2D, and ii. diabetes duration between 3 months and 10 years.
- Previous history of diabetic ketoacidosis (DKA) or ketosis (defined as β-hydroxybutyrate level ≤ 0.3 mmol/L at diabetes diagnosis or any time after).
- Current use of exogenous insulin,
- Poorly controlled diabetes defined as HbA1c >8%,
- Other chronic or acute illness,
- Abnormal liver, thyroid, gonadal or adrenal functions,
- Renal insufficiency defined by eGFR (estimated glomerular filtration rate) <90 mL/min/1.73 m2,
- Medications other than metformin,
- Any hormonal replacement therapy, and
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05477134
|Contact: Mustafa Tosur, MDfirstname.lastname@example.org|
|Contact: Lori Maloneemail@example.com|
|United States, Texas|
|Texas Children's Hospital / Baylor College of Medicine||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: Mustafa Tosur, MD firstname.lastname@example.org|
|Principal Investigator:||Mustafa Tosur, MD||Baylor College of Medicine|
|Responsible Party:||Mustafa Tosur, Assistant Professor of Pediatrics, Baylor College of Medicine|
|Other Study ID Numbers:||
|First Posted:||July 28, 2022 Key Record Dates|
|Last Update Posted:||February 8, 2023|
|Last Verified:||February 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Pediatric type 2 diabetes
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Endocrine System Diseases